Alkermes efforts to create its own line of wholly-owned products beyond its side business as a formulation expert have not been the most successful so far. In fact, data released Jan. 21 could sideline one of its most promising efforts.
The biotech announced results from closely-watched Phase III trials of major depressive disorder therapy ALKS-5461. Both the FORWARD-3 trial and...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
